Skip to main content

Table 3 Baseline characteristics and conversion to type 2 diabetes (T2DM) according to the genotypes of SNP rs3781907 at UCP3 gene

From: Variation in the UCP2 and UCP3genes associates with abdominal obesity and serum lipids: The Finnish Diabetes Prevention Study

 

Genotype

  
 

AA

AG

GG

p b

q

n (M/F)a

221 (73/148)

233 (79/154)

48 (13/35)

0.645

0.714

Age (years)

56 ± 7

55 ± 7

53 ± 7

0.077c

0.421

Weight (kg)

86.3 ± 14.6

85.8 ± 13.5

87.3 ± 15.9

0.878

0.924

BMI (kg/m2)

31.3 ± 4.8

31.1 ± 4.2

31.6 ± 5.2

0.991

0.954

Waist-to-hip ratio

0.92 ± 0.07

0.92 ± 0.07

0.93 ± 0.08

0.583

0.067

Fasting plasma glucose (mmol/l)

6.2 ± 0.8

6.1 ± 0.7

6.2 ± 0.7

0.295

0.047

Fasting serum insulin (pmol/l)

85 ± 40

92 ± 51

86 ± 30

0.665c

0.070

Serum total cholesterol (mmol/l)

5.5 ± 0.9

5.7 ± 0.9

5.9 ± 1.0

0.005

0.006

Serum LDL-cholesterol (mmol/l)

3.5 ± 0.8

3.7 ± 0.8

3.9 ± 1.0

0.004

0.006

Serum HDL-cholesterol (mmol/l)

1.22 ± 0.29

1.22 ± 0.30

1.17 ± 0.25

0.834

0.081

Serum triglycerides (mmol/l)

1.69 ± 0.73

1.74 ± 0.83

1.81 ± 0.70

0.558

0.066

Total cholesterol-to-HDL-cholesterol ratio

4.73 ± 1.22

4.90 ± 1.26

5.15 ± 1.15

0.045

0.013

Converters to T2DM (n/%)a

72/33%

89/38%

23/48%

0.039

0.394

  1. Data are means ± SD
  2. aχ2 test
  3. b Univariate ANOVA, adjusted for age and sex (anthropometric measurements), for age, sex and BMI (glucose, insulin), or for age, sex, BMI, and the use of cholesterol lowering medication (lipids)
  4. c Kruskal-Wallis test